---
title: "Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288475874.md"
description: "On June 1, 2026, Equillium, Inc. (Nasdaq: EQ), a biotechnology company focusing on developing treatments for severe autoimmune and inflammatory conditions, disclosed the granting of an inducement award by its Compensation Committee. This award comprised nonstatutory stock options allowing the purchase of 145,000 common shares to a newly hired individual under Equillium’s 2024 Inducement Plan. The stock option was approved as a significant inducement for the employee's recruitment, following Nasdaq Listing Rule 5635(c)(4)."
datetime: "2026-06-02T20:17:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288475874.md)
  - [en](https://longbridge.com/en/news/288475874.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288475874.md)
generator: "portal-rs"
---

# Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On June 1, 2026, Equillium, Inc. (Nasdaq: EQ), a biotechnology company focusing on developing treatments for severe autoimmune and inflammatory conditions, disclosed the granting of an inducement award by its Compensation Committee. This award comprised nonstatutory stock options allowing the purchase of 145,000 common shares to a newly hired individual under Equillium’s 2024 Inducement Plan. The stock option was approved as a significant inducement for the employee's recruitment, following Nasdaq Listing Rule 5635(c)(4).

### Related Stocks

- [EQ.US](https://longbridge.com/en/quote/EQ.US.md)

## Related News & Research

- [Equillium (NASDAQ:EQ) Announces Earnings Results](https://longbridge.com/en/news/295863022.md)
- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [Longeveron announces 1-for-10 reverse stock split effective Aug. 26](https://longbridge.com/en/news/296824023.md)
- [Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296801308.md)
- [Tiziana Life Sciences launches Phase 2a BANYAN trial of intranasal foralumab in ALS](https://longbridge.com/en/news/296776352.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**